Adept Neuro SA (Lausanne, Switzerland), a joint venture of DIXI Medical (Le Locle, Switzerland, and Besançon, France) and Aleva Neurotherapeutics SA (Lausanne, Switzerland) developing a new generation of intracerebral stereoelectroencephalography (SEEG) electrodes facilitating localization and thermocoagulation of the epileptogenic zones, today announced that it has reached a significant milestone in the development of MEMS-enabled smart SEEGs electrodes.
MEMS are micro-electro-mechanical systems allowing for miniaturization and great flexibility of design.
DIXI Medical will be investing its second tranche into Adept Neuro well ahead of the previously scheduled date, as per its development agreement. DIXI Medical is now targeting regulatory certifications, both in the US and the EU. It expects to have its new product generation on the US market in H1’2022 and a follow-up product with enhanced sensing capabilities that will be a game-changer for practitioners and patients by H2’2023.
“We are impressed how far we have come in the past 24 months and are pleased to switch our collaboration into higher gear with this next investment tranche,“ said Frederic Koehn, CEO of DIXI Medical. “We have been equally impressed with what Adept’s MEMS technology can do in providing new product features and capabilities for our existing customers. Dixi is continuing to invest into new manufacturing and supply infrastructure in order to be ready for the commercial-scale production of SEEGs electrodes for drug-refractory epilepsy patients.“
Dr. Andre Mercanzini, Founder of Aleva Neurotherapeutics and Executive Chairman of Adept Neuro, added: “Our team at Adept has been moving quickly and we are well ahead of our own optimistic expectations. Dixi has been a formidable partner, and their existing sales channel and loyal customer base ensures a rapid uptake of our innovative SEEGs solutions. Furthermore, Dixi’s manufacturing base has been able to quickly absorb the advantages of MEMS technology on their assembly lines, which further ensures quality and time to market for the technology.”